The acute sensory neuronopathy syndrome: A distinct clinical entity

A. B. Sterman, H. H. Schaumburg, A. K. Asbury

Research output: Contribution to journalArticle

131 Citations (Scopus)

Abstract

Four to twelve days following initial antibiotic treatment for a febrile illness, three adults suddenly experienced numbness and pain over the face and entire body. Each had received a penicillin or a semisynthetic derivative, and two patients also received other antibiotics. Signs appeared rapidly and included profound sensory ataxia, areflexia, and widespread sensory loss, primarily of large fiber modalities (proprioceptive sensibility). Slowed or absent sensory conduction was found. There was no weakness, and electrical study of muscle and motor nerve conduction was normal in all. The cerebrospinal fluid was acellular, and protein levels were elevated to 126 and 175 mg/dl in two cases and were normal in the other. Presently, all have a severe, static, residual sensory deficit. During follow-up of five years, no evidence of neoplastic disease or immunological disorder has appeared. Because of the rapid onset, widespread and pure sensory involvement, and poor recovery, the lesion is most likely confined to the dorsal root and gasserian ganglia (sensory neuronopathy). This pattern resembles that of the experimental lesions induced by doxorubicin and pyridoxine. It appears likely that either the previously administered antibiotics or the illness for which they were administered were of pathogenetic importance. We designate this previously unrecognized disorder the acute sensory neuronopathy syndrome and suggest that it represents a distinct, readily identifiable clinical entity.

Original languageEnglish (US)
Pages (from-to)354-358
Number of pages5
JournalAnnals of Neurology
Volume7
Issue number4
StatePublished - 1980

Fingerprint

Anti-Bacterial Agents
Sensation Disorders
Trigeminal Ganglion
Pyridoxine
Facial Pain
Hypesthesia
Neural Conduction
Immune System Diseases
Spinal Ganglia
Ataxia
Penicillins
Doxorubicin
Cerebrospinal Fluid
Fever
Muscles
Proteins
Therapeutics

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Sterman, A. B., Schaumburg, H. H., & Asbury, A. K. (1980). The acute sensory neuronopathy syndrome: A distinct clinical entity. Annals of Neurology, 7(4), 354-358.

The acute sensory neuronopathy syndrome : A distinct clinical entity. / Sterman, A. B.; Schaumburg, H. H.; Asbury, A. K.

In: Annals of Neurology, Vol. 7, No. 4, 1980, p. 354-358.

Research output: Contribution to journalArticle

Sterman, AB, Schaumburg, HH & Asbury, AK 1980, 'The acute sensory neuronopathy syndrome: A distinct clinical entity', Annals of Neurology, vol. 7, no. 4, pp. 354-358.
Sterman AB, Schaumburg HH, Asbury AK. The acute sensory neuronopathy syndrome: A distinct clinical entity. Annals of Neurology. 1980;7(4):354-358.
Sterman, A. B. ; Schaumburg, H. H. ; Asbury, A. K. / The acute sensory neuronopathy syndrome : A distinct clinical entity. In: Annals of Neurology. 1980 ; Vol. 7, No. 4. pp. 354-358.
@article{36d9e9fd8349461a8bfe35e12354700d,
title = "The acute sensory neuronopathy syndrome: A distinct clinical entity",
abstract = "Four to twelve days following initial antibiotic treatment for a febrile illness, three adults suddenly experienced numbness and pain over the face and entire body. Each had received a penicillin or a semisynthetic derivative, and two patients also received other antibiotics. Signs appeared rapidly and included profound sensory ataxia, areflexia, and widespread sensory loss, primarily of large fiber modalities (proprioceptive sensibility). Slowed or absent sensory conduction was found. There was no weakness, and electrical study of muscle and motor nerve conduction was normal in all. The cerebrospinal fluid was acellular, and protein levels were elevated to 126 and 175 mg/dl in two cases and were normal in the other. Presently, all have a severe, static, residual sensory deficit. During follow-up of five years, no evidence of neoplastic disease or immunological disorder has appeared. Because of the rapid onset, widespread and pure sensory involvement, and poor recovery, the lesion is most likely confined to the dorsal root and gasserian ganglia (sensory neuronopathy). This pattern resembles that of the experimental lesions induced by doxorubicin and pyridoxine. It appears likely that either the previously administered antibiotics or the illness for which they were administered were of pathogenetic importance. We designate this previously unrecognized disorder the acute sensory neuronopathy syndrome and suggest that it represents a distinct, readily identifiable clinical entity.",
author = "Sterman, {A. B.} and Schaumburg, {H. H.} and Asbury, {A. K.}",
year = "1980",
language = "English (US)",
volume = "7",
pages = "354--358",
journal = "Annals of Neurology",
issn = "0364-5134",
publisher = "John Wiley and Sons Inc.",
number = "4",

}

TY - JOUR

T1 - The acute sensory neuronopathy syndrome

T2 - A distinct clinical entity

AU - Sterman, A. B.

AU - Schaumburg, H. H.

AU - Asbury, A. K.

PY - 1980

Y1 - 1980

N2 - Four to twelve days following initial antibiotic treatment for a febrile illness, three adults suddenly experienced numbness and pain over the face and entire body. Each had received a penicillin or a semisynthetic derivative, and two patients also received other antibiotics. Signs appeared rapidly and included profound sensory ataxia, areflexia, and widespread sensory loss, primarily of large fiber modalities (proprioceptive sensibility). Slowed or absent sensory conduction was found. There was no weakness, and electrical study of muscle and motor nerve conduction was normal in all. The cerebrospinal fluid was acellular, and protein levels were elevated to 126 and 175 mg/dl in two cases and were normal in the other. Presently, all have a severe, static, residual sensory deficit. During follow-up of five years, no evidence of neoplastic disease or immunological disorder has appeared. Because of the rapid onset, widespread and pure sensory involvement, and poor recovery, the lesion is most likely confined to the dorsal root and gasserian ganglia (sensory neuronopathy). This pattern resembles that of the experimental lesions induced by doxorubicin and pyridoxine. It appears likely that either the previously administered antibiotics or the illness for which they were administered were of pathogenetic importance. We designate this previously unrecognized disorder the acute sensory neuronopathy syndrome and suggest that it represents a distinct, readily identifiable clinical entity.

AB - Four to twelve days following initial antibiotic treatment for a febrile illness, three adults suddenly experienced numbness and pain over the face and entire body. Each had received a penicillin or a semisynthetic derivative, and two patients also received other antibiotics. Signs appeared rapidly and included profound sensory ataxia, areflexia, and widespread sensory loss, primarily of large fiber modalities (proprioceptive sensibility). Slowed or absent sensory conduction was found. There was no weakness, and electrical study of muscle and motor nerve conduction was normal in all. The cerebrospinal fluid was acellular, and protein levels were elevated to 126 and 175 mg/dl in two cases and were normal in the other. Presently, all have a severe, static, residual sensory deficit. During follow-up of five years, no evidence of neoplastic disease or immunological disorder has appeared. Because of the rapid onset, widespread and pure sensory involvement, and poor recovery, the lesion is most likely confined to the dorsal root and gasserian ganglia (sensory neuronopathy). This pattern resembles that of the experimental lesions induced by doxorubicin and pyridoxine. It appears likely that either the previously administered antibiotics or the illness for which they were administered were of pathogenetic importance. We designate this previously unrecognized disorder the acute sensory neuronopathy syndrome and suggest that it represents a distinct, readily identifiable clinical entity.

UR - http://www.scopus.com/inward/record.url?scp=0018839133&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018839133&partnerID=8YFLogxK

M3 - Article

C2 - 6246836

AN - SCOPUS:0018839133

VL - 7

SP - 354

EP - 358

JO - Annals of Neurology

JF - Annals of Neurology

SN - 0364-5134

IS - 4

ER -